

Don't miss our webinar presented by Nature Research!

High-sensitivity immunoassays for biomarkers of Huntington's disease

Immunoassays for neurodegeneration biomarkers

If disease-modifying therapies for conditions such as Huntington's disease are to become reality, clinicians and researchers need validated biomarkers. Different biomarkers will be required to monitor disease development (or regression) in the clinic, and to support decision-making in the drug development process.

Evotec has a wide portfolio of robust and reliable immunoassays to investigate changes in neurodegenerative biomarker levels, including the Huntingtin protein (HTT). Evotec's assay detects mutant HTT proteins in the cerebrospinal fluid of patients with Huntington's disease, and is sensitive enough to detect decreases in mutant HTT after the administration of an HTT-lowering agent in phase II trials.

This webcast will focus on the establishment of this high-sensitivity immunoassay using Single Molecule Counting (SMC[™]) technology to detect mutant HTT. The speakers will discuss its performance across several assay platforms, and how to validate it using Good Laboratory Practice.

Monday, October 19, 2020

8AM PDT | 11AM EDT | 4PM BST | 5PM CEST

In this webcast, you will learn about:

What critical steps are needed to establish robust biomarker assays?

What are the challenges of moving biomarker assays from a research grade non-GLP laboratory to a clinical-grade GLP laboratory?

What are the best ways to plan validation assessments and set related acceptance criteria, following regulatory guidelines, in order to analyze a pivotal clinical-efficacy biomarker?



Dr. Chantal Bazenet
Group Leader, HD Research and
Translational Sciences Dept.
Evotec SE, Germany



Dr. Elena Vicentini
Senior Supervisor Immunoassays and
Biopharmaceuticals, Preclinical
Development
Aptuit Srl, an Evotec Company, Italy

To register for the event, visit: <https://www.workcast.com/register?cpak=4775647976053763>